ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Gynecol Oncol · 2026-08-20

In 36 patients with newly diagnosed HR-deficient stage III/IV ovarian cancer, neoadjuvant niraparib gave a lower pre-surgery response rate than platinum-taxane chemotherapy (31.6% vs 70.6%); the cohort closed early for futility. Grade ≥3 adverse events: 42% vs 59%.

RCTn = 36
Westin et al. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial
Oncology · Gynecol Oncol · 2026-07-01

Secondary analysis of the PRIMA trial in newly diagnosed advanced ovarian cancer: first-line niraparib maintenance showed no difference in overall quality of life versus placebo; disease progression caused sustained quality-of-life deterioration in both arms (post hoc).

Secondary analysis
Shahin et al. Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.